AJANTPHARM / Q4-FY24 / risks

Keep the risk register visible.

Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ4-FY24 · 2024-05-14Back to quarter ↗

Risk intelligence

Material risks this quarter

Red Sea freight disruption impact

Increased transit times and freight costs due to Red Sea crisis could add ~INR 30 crore to expenses, potentially pressuring margins.

medium

US price erosion may be higher than guided

An analyst questioned whether high single-digit price erosion is aggressive; management acknowledged it's their estimate but could be worse.

medium

Institutional business unpredictability

Africa institutional business (antimalarials) is lumpy and dependent on procurement agency schedules; Q4 benefited from preponed orders, which may not recur.

medium

M&A valuations remain high for premium assets

Management noted that while valuations have tapered, premium specialty portfolios are still expensive, limiting inorganic growth options.

low